1. Generics Bulletin
  2. >>Products

‘You Have To Play On A Pretty Broad Part Of The Piano’: Fresenius Kabi On Biosimilar Commitment

Exclusive Interview With Fresenius Kabi’s Biopharma Business President, Michael Schönhofen

 
• By Dean Rudge

During a broad and wide-ranging interview, taking place in the aftermath of Fresenius Kabi’s entry into the US adalimumab biosimilar market, president of the firm’s Biopharma business, Michael Schönhofen, talks about Kabi’s ambitions in the space, and how it is positioned to be a long-term player.

Fresenius Kabi logo on building
• Source: Shutterstock

“We want to be a first-class biosimilar supplier worldwide. And here, I would say, we are on a really good pathway,” the president of Fresenius Kabi AG’s Biopharma business, Michael Schönhofen, tells Generics Bulletin.

Speaking exclusively in the weeks following the launch of the firm’s Idacio (adalimumab-aacf) biosimilar to Humira in the US as part of the eight-strong second wave to reach the market, Schönhofen discusses the seminal event for industry, alongside his perception and expectations for the growing US

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.